Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
GPC Biotech AG (Frankfurt Stock Exchange: GPC) today reported that pre-clinical data on RGB-286638, the Company?s multi-targeted protein kinase inhibitor, are being presented at...
GPC Biotech AG (Frankfurt Stock Exchange: GPC) today reported financial results for the fourth quarter and fiscal year ended December 31, 2008. The results are being reported in...
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) and Agennix, Incorporated today announced that the two oncology-focused biotechnology companies have signed a...
GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that enrollment has opened in a Phase 1 study evaluating RGB-286638 in patients with advanced solid...
GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today reported financial results for the third quarter and first nine months ended September 30, 2008. First...
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that the Company will give a corporate presentation at the upcoming Rodman & Renshaw Annual Global...
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that the Company has received notice from Celgene Corporation of its decision to terminate its...
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) reported that the Company has been informed by its partner for satraplatin in Europe that they plan to withdraw the...
GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, a novel, oral platinum...
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that the Company will give a corporate presentation at the upcoming Needham 7th Annual Biotechnology...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
